2-methyl-nonanoic acid amide | 91342-80-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-methyl-nonanoic acid amide
• 英文别名: (+/-)-Methyl-heptyl-essigsaeure-amid；2-Methyl-nonansaeure-amid；2-Methylnonanoic acid amide；2-methylnonanamide
• CAS: 91342-80-2
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: KCVKVMKMXZXHEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基壬腈 在 盐酸 作用下， 生成 2-methyl-nonanoic acid amide
  参考文献：
  名称：

  de Hoffmann; Barbier, Bulletin des Societes Chimiques Belges, 1936, vol. 45, p. 570

  摘要：

  DOI：

文献信息

• [EN] 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS<br/>[FR] UTILISATION DE COMPOSES HETEROARYLES A SUBSTITUTION 3-ALKYLIDENEHYDRAZINO EN TANT QU'ACTIVATEURS DU RECEPTEUR DE LA THROMBOPOIETINE
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2004108683A1

  公开（公告）日：2004-12-16

  A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14; aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10; alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14; aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  化合物的结构式（1）如下：其中A是氮原子或CR4，B是氧原子、硫原子或NR9（但当A是氮原子时，B不是NH），R1是C2-14芳基，L1是键，CR10R11、氧原子、硫原子或NR12，X是OR13、SR13或NR14NR15，R2是氢原子、甲酰基、C1-10烷基或类似物，L2是键或类似物，L3是键，CR17R18、氧原子、硫原子或NR19，L4是键，CR20R21、氧原子、硫原子或NR22，Y是氧原子、硫原子或NR23，R3是C2-14芳基、化合物的互变异构体、前药或药学上可接受的盐或其溶剂化合物。
• ALPHA-SUBSTITUTED VINYLTIN COMPOUND
  申请人：Tatsuta Kuniaki

  公开号：US20090023939A1

  公开（公告）日：2009-01-22

  To provide α-substituted vinyltin useful for the search for function-developing substances such as pharmaceuticals/agrichemicals and functional materials and for the construction of a compound library. An α-substituted vinyltin compound represented by the formula (1), a tautomer or salt of the compound or a solvate thereof: R 2 CH═C(R 3 )Sn(R 1 ) 3 (1) wherein R 1 is a C 1-10 alkyl group, a C 2-14 aryl group or the like, R 2 is a C 2-14 aryl group, a C 2-9 heterocyclyl group, a C 3-10 cycloalkyl group or the like, and R 3 is a carbamoyl group, a thiocarbamoyl group, an isocyanate group, an isothiocyanate group, a formylamino group, a thioformylamino group, an isonitrile group, an urea group, a carbamate group or the like.

  提供α-取代的乙烯基锡，用于寻找功能发展物质，如药物/农药和功能材料，以及用于构建化合物库。由下式表示的α-取代的乙烯基锡化合物（1）或其互变异构体或盐或溶剂合物：R2CH═C(R3)Sn(R1)3（1）其中R1是C1-10烷基，C2-14芳基或类似物，R2是C2-14芳基，C2-9杂环基，C3-10环烷基或类似物，R3是氨基甲酰基，硫氨基甲酰基，异氰酸酯基，异硫氰酸酯基，甲酰氨基基，硫代甲酰氨基基，异腈基，脲基，氨基甲酸酯基或类似物。
• OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST
  申请人：Shibasaki Masakatsu

  公开号：US20100298559A1

  公开（公告）日：2010-11-25

  There is provided a novel optically active dinickel complex and/or a production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst. An optically active dinickel complex of Formula (I) or Formula (I′): [where R 0 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a halogen atom, a C 1-10 alkyl group or a C 1-10 alkoxy group, etc., R 2 and R 3 together form, together with a benzene ring bonded to them, a naphthalene ring, etc. A novel production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst.

  提供了一种新型光学活性二镍配合物和/或使用该二镍配合物作为催化剂进行不对称Mannich反应制备光学活性胺的生产方法。公式（I）或公式（I′）的光学活性二镍配合物：[其中R0、R1、R2、R3、R4、R5、R6和R7分别独立地是氢原子、卤素原子、C1-10烷基或C1-10烷氧基等，R2和R3连同与它们结合的苯环形成萘环等。使用该二镍配合物作为催化剂，通过不对称Mannich反应制备光学活性胺的新型生产方法。
• [EN] CHEMICAL PROCESS FOR OPENING RING COMPOUNDS<br/>[FR] PROCÉDÉ CHIMIQUE POUR OUVRIR DES COMPOSÉS CYCLIQUES
  申请人：CHEMO IBERICA SA

  公开号：WO2013014191A1

  公开（公告）日：2013-01-31

  It is described a process for the opening of lactone or lactam rings useful in the synthesis of pharmaceutically active compounds and the intermediates thereof, particularly Aliskiren. It has found that by selecting a type of solvent it is possible to obtain excellent yields and high optical and chemical purity of the isolated products.

  本文描述了一种开放内酯或内酰胺环的过程，该过程对于合成药物活性化合物及其中间体，特别是Aliskiren非常有用。研究发现，通过选择一种类型的溶剂，可以获得出色的产率和高光学和化学纯度的分离产物。
• [EN] SPIROCYCLIC METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES SPIROCYCLIQUES
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：WO1998008850A1

  公开（公告）日：1998-03-05

  (EN) The invention provides compounds of formula (I) as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.(FR) La présente invention concerne des composés convenant comme inhibiteurs de métalloprotéases et qui sont représentés par la formule générale (I) telle qu'elle est revendiquée, mais aussi l'un de ses isomères optiques, l'un de ses diastéréomères ou énantiomères, l'un de ses sels pharmaceutiquement admis, ou encore l'un de ses alcoxylamides biohydrolysables, l'un de ses esters, ou l'un de ses imides. L'invention concerne également des composés, des compositions pharmaceutiques et des thérapies dirigées contre des affections, des troubles et des états caractérisés par une activité de métalloprotéase, lesquelles thérapies impliquent l'utilisation de ces composés ou de compositions pharmaceutiques contenant ces composés.

  本发明提供了公式(I)所描述的化合物，或其光学异构体、对映异构体或手性异构体，或其药学上可接受的盐，或其可生物降解的酰胺、酯或亚酰胺，作为金属蛋白酶的抑制剂。还公开了使用这些化合物或含有它们的药物组合物治疗由金属蛋白酶活性所特征的疾病、紊乱和状况的方法和制药组合物。